Clearside Biomedical (FRA:CLM) Loans Receivable : €0.00 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Clearside Biomedical Loans Receivable?

Clearside Biomedical's Loans Receivable for the quarter that ended in Sep. 2024 was €0.00 Mil.

Clearside Biomedical Loans Receivable Historical Data

The historical data trend for Clearside Biomedical's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clearside Biomedical Loans Receivable Chart

Clearside Biomedical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Loans Receivable

Get a 7-Day Free Trial

Clearside Biomedical Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Clearside Biomedical Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Clearside Biomedical Loans Receivable Related Terms

Thank you for viewing the detailed overview of Clearside Biomedical's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Clearside Biomedical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clearside Biomedical Inc (FRA:CLM) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

CLSD:USA

Address

900 North Point Parkway, Suite 200, Alpharetta, GA, USA, 30005

Website

https://www.clearsidebio.com

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.